Exogenus
Therapeutics
Exogenus Therapeutics is an early-stage research and development company developing healthcare solutions based on Extracellular Vesicles (EVs) and Exosomes. Founded in 2015,
Exogenus is a pioneer in the field of EVs/Exosome-based therapeutics, and a recognized innovator in Umbilical Cord Blood clinical use. Leveraging on its experience and recognition in this space, Exogenus mission is to foster a new era of EVs/Exosomes-based solutions to solve major healthcare challenges, based on the development of its own products, and providing guidance to other partners developing this type technologies for clinical use.
Latest news
New Publication Out: Optimized Method for EV Production
A paper entitled “Development of an optimized and scalable method for isolation of umbilical cord blood‐derived small extracellular vesicles for future clinical use” was just published in...
Exogenus Therapeutics wins grant to study umbilical cord blood exosomes for the treatment of lung inflammation
Exogenus Therapeutics is currently developing an innovative treatment for acute lung inflammation, based on naturally-occurring vesicles that facilitate cellular communication. After...
Exogenus Therapeutics presents at the Exosome Based Therapeutic Development Summit 2020
Joana Correia, CEO and CSO of Exogenus Therapeutics is an invited speaker at the 2nd Exosome Based Therapeutic Development Summit, taking place during November 11-12 (online). Joana will...